These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 39111120

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Discovery of N-(1,3,4-thiadiazol-2-yl)benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR/HER-2 dual-target inhibitors against cancer growth and angiogenesis.
    Li XY, Wang DP, Li S, Xue WH, Qian XH, Liu KL, Li YH, Lin QQ, Dong G, Meng FH, Jian LY.
    Bioorg Chem; 2022 Feb; 119():105469. PubMed ID: 34915285
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C, Xu S, Peng L, Zhang B, Zhang H, Hu Y, Zheng P, Zhu W.
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Zou M, Li J, Jin B, Wang M, Chen H, Zhang Z, Zhang C, Zhao Z, Zheng L.
    Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway.
    Wang Z, Liu L, Dai H, Si X, Zhang L, Li E, Yang Z, Chao G, Zheng J, Ke Y, Lihong S, Zhang Q, Liu H.
    Bioorg Med Chem; 2021 Aug 01; 43():116265. PubMed ID: 34192644
    [Abstract] [Full Text] [Related]

  • 7. In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models.
    Das D, Xie L, Wang J, Shi J, Hong J.
    Bioorg Chem; 2020 Jun 01; 99():103790. PubMed ID: 32279037
    [Abstract] [Full Text] [Related]

  • 8. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
    Alkahtani HM, Abdalla AN, Obaidullah AJ, Alanazi MM, Almehizia AA, Alanazi MG, Ahmed AY, Alwassil OI, Darwish HW, Abdel-Aziz AA, El-Azab AS.
    Bioorg Chem; 2020 Jan 01; 95():103461. PubMed ID: 31838290
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J, Wan S, Wang G, Zhang T, Li Z, Tian Y, Yu Y, Wu X, Zhang J.
    Eur J Med Chem; 2016 Aug 08; 118():276-89. PubMed ID: 27132165
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.
    Zhang B, Xu Z, Liu Q, Xia S, Liu Z, Liao Z, Gou S.
    Bioorg Chem; 2021 Dec 08; 117():105420. PubMed ID: 34655841
    [Abstract] [Full Text] [Related]

  • 11. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J, Ren H, Zhao M, Chong Y, Zhao W, He Y, Zhao Y, Zhang H, Qi C.
    Eur J Med Chem; 2017 Sep 29; 138():669-688. PubMed ID: 28711702
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFRL858R/T790M kinase inhibitors.
    Ding S, Dong X, Gao Z, Zheng X, Ji J, Zhang M, Liu F, Wu S, Li M, Song W, Shen J, Duan W, Liu J, Chen Y.
    Bioorg Chem; 2022 Jan 29; 118():105471. PubMed ID: 34798457
    [Abstract] [Full Text] [Related]

  • 13. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study.
    El Hamaky NFM, Hamdi A, Bayoumi WA, Elgazar AA, Nasr MNA.
    Bioorg Chem; 2024 Jul 29; 148():107437. PubMed ID: 38749114
    [Abstract] [Full Text] [Related]

  • 14. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF, Bayoumi AH, El-Morsy AM, Sobhy M, Hagras M.
    Bioorg Chem; 2021 Nov 29; 116():105325. PubMed ID: 34507234
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H2S) donors as potent EGFR inhibitors against L858R resistance mutation.
    Zheng YG, Zhang WQ, Meng L, Wu XQ, Zhang L, An L, Li CL, Gao CY, Xu L, Liu Y.
    Eur J Med Chem; 2020 Sep 15; 202():112522. PubMed ID: 32619886
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFRT790M mutant cell lines.
    Zhao L, Fan T, Shi Z, Ding C, Zhang C, Yuan Z, Sun Q, Tan C, Chu B, Jiang Y.
    Eur J Med Chem; 2021 Mar 05; 213():113173. PubMed ID: 33493830
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B, Altıntop MD, Radwan MO, Özdemir A, Otsuka M, Fujita M, Ciftci HI.
    Eur J Med Chem; 2019 Nov 15; 182():111648. PubMed ID: 31493743
    [Abstract] [Full Text] [Related]

  • 18. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
    Yassen AS, Elshihawy HE, Said MM, Abouzid KA.
    Chem Pharm Bull (Tokyo); 2014 Nov 15; 62(5):454-66. PubMed ID: 24789927
    [Abstract] [Full Text] [Related]

  • 19. Novel 2-[thio]acetamide linked quinazoline/1,2,4-triazole/chalcone hybrids: Design, synthesis, and anticancer activity as EGFR inhibitors and apoptotic inducers.
    Abdelkhalek AS, Kothayer H, Soltan MK, Ibrahim SM, Elbaramawi SS.
    Arch Pharm (Weinheim); 2024 Jul 15; 357(7):e2300627. PubMed ID: 38593298
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors.
    Zhou Z, He J, Yang F, Pan Q, Yang Z, Zheng P, Xu S, Zhu W.
    Bioorg Chem; 2021 Jul 15; 112():104848. PubMed ID: 33819737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.